Portfolio AOP Health Austria
A Product overview with focus on Rare Diseases.
AOP Health's focus is on integrated therapies for rare diseases and in critical care. The portfolio comprises products in the following therapeutic areas: Hemato-oncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders and Critical Care. AOP Health’s strategic goal is to constantly deliver new treatment options with respect to rare diseases and critical care.
Empesin® is used for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. A catecholamine refractory hypotension is present if the mean arterial blood pressur cannot be stabilized to 65 – 75 mmHg despite adequate volume substitution and application of catecholamines.
Esmocard® is indicated for supraventricular tachycardia and for the rapid control of the ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short-acting agent is desirable.
"Complete or partial reversal of CNS depressive effects, especially respiratory depression, caused by natural or synthetic opioids and partial agonist/antagonist opioids. It is also used to diagnose a suspected acute opioid overdose or intoxication or to reduce the effect of opioids, which were used for anesthesia in operations."
Adepend is used as part of a comprehensive treatment program against alcoholism to reduce the risk of relapse, as support treatment in abstinence and to reduce the craving for alcohol.
Landiolol hydrochloride is indicated for supraventricular tachycardia and for rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Landiolol hydrochloride is also indicated for non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requires specific intervention. Landiolol is not intended for use in chronic settings.